VEGFA and colorectal carcinoma: Bevacizumab, a recombinant humanized monoclonal antibody, is used as a targeted therapy for CRC as it specifically targets the isoforms of vascular endothelial growth factor A (VEGF-A), a ligand that binds to VEGF receptors 1 and 2 (25).